Orogen Royalties Inc. operates as a mineral exploration company. It primarily explores for gold, copper, silver, and precious and base metal deposits. The company was formerly known as Evrim Resources Corp. and changed its name to Orogen Royalties Inc. in August 2020. Orogen Royalties Inc. was incorporated in 2005 and is headquartered in Vancouver, Canada.

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.

Peak Rare Earths Limited engages in the exploration and evaluation of mineral licenses in Tanzania. The company explores for neodymium and praseodymium rare earth mixed oxides. It holds a 100% interest in the Ngualla Rare Earth project located in southern Tanzania. The company was formerly known as Peak Resources Limited and changed its name to Peak Rare Earths Limited in December 2021. Peak Rare Earths Limited was incorporated in 2005 and is based in Perth, Australia.

Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.

Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.

ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

Eco (Atlantic) Oil & Gas Ltd. engages in the identification, acquisition, exploration, and development of the petroleum, natural gas, and shale gas properties in the Republic of Namibia and the Co-Operative Republic of Guyana. The company holds a 15% working interest in the Orinduik block comprising 1,800 square kilometers located in the Suriname Guyana basin; and interests in the Canje Block covering an area of 4,800 square kilometers located in Guyana. It also holds 85% working interest in the Cooper Block, which covers an area of approximately 5,788 square kilometers; 85%working interest in the Sharon Block, which covers an area of approximately 5,700 square kilometers; 85% working interest in the Guy License covering an area of approximately 11,457 square kilometers; and an 85% working interest in the Tamar Block that covers an area of approximately 5,649 square kilometers located in the Walvis Basin offshore, Namibia. In addition, the company engages in the development of solar projects. Eco (Atlantic) Oil & Gas Ltd. is headquartered in Toronto, Canada.

Solarvest BioEnergy Inc. engages in the development of algal-based production systems to produce natural based green commercial products in Canada and internationally. The company provides human nutrition products, including omega-3; and pharmaceutical ingredients for human health comprising cannabinoids in algae and bone morphogenetic protein for the treatment of repairing bone fractures. It has a collaborative research and development agreement with FSD Pharma Inc. to develop algae-based pharmaceutical grade cannabinoids. The company was incorporated in 2005 and is based in Vancouver, Canada.

ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

Magnis Energy Technologies Limited engages in the exploration and development of mineral properties in the United States, Australia, and Tanzania. It primarily explores for natural flake graphite used in batteries for storing electrical energy. The company holds a 100% interest in the Nachu graphite project located in southeast Tanzania. It also engages in the lithium-ion Battery investments. The company was formerly known as Magnis Resources Limited and changed its name to Magnis Energy Technologies Limited in November 2018. Magnis Energy Technologies Limited was incorporated in 2005 and is based in Sydney, Australia.